ONE-YEAR RETROSPECTIVE ANALYSIS OF DESIDUSTAT: A PROMISING HIF-PHI FOR ANEMIA MANAGEMENT IN DIALYSIS-DEPENDENT CKD PATIENTS

8 Feb 2025 12 a.m. 12 a.m.
WCN25-AB-2264, Poster Board= SAT-077

Introduction:

Chronic Kidney Disease induced anemia is due to relative deficiency of Erythropoietin from kidneys. In Dialysis dependent category patient become dependent on Erythrocyte stimulating agents. Newer HIF PHIs showed promise of correcting anemia in Dialysis dependent CKD anemia patients. Our study is a retrospective analysis of usage of HIF PHI in Dialysis dependent patients.

Methods:

This is a single-center retrospective analysis of one year of experience at Shrimann Hospital, Jalandhar. We enrolled patients who are diagnosed with CKD—anemia and dialysis-dependent at our center. These patients were started on Treatment of Desidustat 100 mg and 50 mg thrice a week and every month their Hemoglobin monitored. 

Results:

Figure 1: Change in Hb (n=58)(p=0.002, One way ANOVA)

In the present study, we have enrolled a total of 58 patients. Out of this, 36 (62%) were male and 22 (38%) were female. All patients received dialysis for 3 times a week. The patient received IV iron according to the iron profile. Out of 57 patients, the majority had Diabetic Kidney Disease (n=42, 72.4%), Hypertension (45, 78.9%), CAD (4, 7%), ADPKD (2, 3.5%), and one case of Post-transplant (1, 1.7%), Multiple Myeloma (1,1.7%), IgAN (1,1.7%),  Majority of our patient received treatment of Desidustat 100 mg (n = 32, 55.2%) and 50 mg (n= 26, 44.8%) for CKD anemia thrice a week. Mena Serum creatinine 7.56 ± 3 mg/dl and eGFR 8.72 ± 5.7 mL/min/1.73m2.  Mean Serum Iron 29.74 ± 46.5 mcg/dl. Baseline Hb at the start of treatment was 8.82 ± 1.8 gm/dl at the end of the study, Hb was 10.35 ± 1.7 gm/dl (p= 0.002, one-way ANOVA) test) shown in Figure 1. The mean difference from the baseline observed was 1.53 gm/dl in dialysis-dependent patients. In the present study, all patients maintained good compliance with the Treatment of Desidustat. Out of 58 patients, we have not observed any thrombosis of AV fistula or Fistula failure, treatment failure and Hyperkalemia with HIF –PHI treatment. 

Conclusions:

Desidustat showed promising outcome in terms of improvement of Hb in CKD – Anemia. Long term one year data showed desidustat is a safe alternative to erythropoietin analogue.

I have no potential conflict of interest to disclose.

I did not use generative AI and AI-assisted technologies in the writing process.